Atezolizumab in non-squamous non-small cell lung cancer

被引：5
|
作者：
Akamine, Takaki [1 ]
Toyokawa, Gouji [1 ]
Tagawa, Tetsuzo [1 ]
Seto, Takashi [2 ]
机构：
[1] Kyushu Univ, Grad Sch Med Sci, Dept Surg & Sci, Higashi Ku, 3-1-1 Maidashi, Fukuoka, Fukuoka 8128582, Japan
[2] Kyushu Natl Canc Ctr, Dept Thorac Oncol, Minami Ku, Fukuoka, Fukuoka, Japan
来源：
JOURNAL OF THORACIC DISEASE | 2018年 / 10卷
关键词：
OPEN-LABEL; 1ST-LINE THERAPY; PHASE-2; TRIAL; EGFR; IMMUNOTHERAPY; PEMBROLIZUMAB; MULTICENTER; BEVACIZUMAB; CHEMOTHERAPY; DOCETAXEL;
D O I：
10.21037/jtd.2018.07.92
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
[No abstract available]
引用
收藏
页码：S3155 / S3159
页数：5
相关论文
共 50 条
  • [41] Cost-Effectiveness Analysis of Atezolizumab Plus Chemotherapy in the First-Line Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer
    Dong Ding
    Huabin Hu
    Mengting Liao
    Yin Shi
    Longjiang She
    Linli Yao
    Youwen Zhu
    Shan Zeng
    Jin Huang
    Advances in Therapy, 2020, 37 : 2116 - 2126
  • [42] Prospects and progress of atezolizumab in non-small cell lung cancer
    Vansteenkiste, Johan
    Wauters, Els
    Park, Keunchil
    Rittmeyer, Achim
    Sandler, Alan
    Spira, Alexander
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2017, 17 (06) : 781 - 789
  • [43] Phase II Trial of Carboplatin, Pemetrexed, Bevacizumab in Advanced non-Small Cell (non-Squamous) Lung Cancer
    Guarino, Michael J.
    Masters, Gregory A.
    Biggs, David D.
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S698 - S698
  • [44] Identification of Immunotherapy Targets in STK11 Mutant Non-Squamous Non-Small Cell Lung Cancer
    Yau, E.
    Glenn, S.
    Papinicalou-Sengos, A.
    Nesline, M.
    Morrison, C.
    Dy, G.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S442 - S442
  • [45] Efficacy of bevacizumab-containing chemotherapy for non-squamous non-small cell lung cancer with bone metastases
    Takaaki Tokito
    Takehito Shukuya
    Hiroaki Akamatsu
    Tetsuhiko Taira
    Akira Ono
    Hirotsugu Kenmotsu
    Tateaki Naito
    Haruyasu Murakami
    Toshiaki Takahashi
    Masahiro Endo
    Nobuyuki Yamamoto
    Cancer Chemotherapy and Pharmacology, 2013, 71 : 1493 - 1498
  • [46] Impact of KRAS mutation on response and outcome of patients with stageIII non-squamous non-small cell lung cancer
    Yagishita, Shigehiro
    Horinouchi, Hidehito
    Sunami, Kuniko S.
    Kanda, Shintaro
    Fujiwara, Yutaka
    Nokihara, Hiroshi
    Yamamoto, Noboru
    Sumi, Minako
    Shiraishi, Kouya
    Kohno, Takashi
    Furuta, Koh
    Tsuta, Koji
    Tamura, Tomohide
    Ohe, Yuichiro
    CANCER SCIENCE, 2015, 106 (10) : 1402 - 1407
  • [47] Molecular testing in older patients treated for an advanced or metastatic non-squamous non-small cell lung cancer
    Lamy, T.
    Cabarrou, B.
    Planchard, D.
    Quantin, X.
    Schneider, S.
    Bringuier, M.
    Besse, B.
    Perol, M.
    Girard, N.
    Schott, R.
    Chouaid, C.
    Ricordel, C.
    Gervais, R.
    Debieuvre, D.
    Audigier-Valette, C.
    Carton, M.
    Filleron, T.
    Simon, G.
    Robain, M.
    Baldini, C.
    ANNALS OF ONCOLOGY, 2021, 32 : S1243 - S1244
  • [48] Clinical efficacy of bevacizumab combined with chemotherapy in the treatment of advanced non-squamous non-small cell lung cancer
    Liu, Yuhua
    Mao, Aihong
    Ma, Qin
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2019, 12 (07): : 9049 - 9057
  • [49] REAL-WORLD PATTERNS OF BIOMARKER TESTING IN METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
    Roncadori, A.
    Massa, I
    Balzi, W.
    Danesi, V
    Rengucci, C.
    Gentili, N.
    Crino, L.
    Delmonte, A.
    Altini, M.
    VALUE IN HEALTH, 2022, 25 (01) : S255 - S255
  • [50] MGA Mutation as a Novel Biomarker for Immune Checkpoint Therapies in Non-Squamous Non-Small Cell Lung Cancer
    Sun, Lei
    Li, Man
    Deng, Ling
    Niu, Yuchun
    Tang, Yichun
    Wang, Yu
    Guo, Linlang
    FRONTIERS IN PHARMACOLOGY, 2021, 12
12345